Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quinacrine mustard
- Development stage
- Discontinued
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Quinacrine mustard is a synthetic small molecule derived from the antimalarial drug quinacrine and chemically modified to include a nitrogen mustard moiety. This modification confers alkylating properties to the compound. Quinacrine mustard acts as a fluorescent DNA-intercalating agent with selectivity for adenine-thymine (AT) base pairs over guanine-cytosine (GC) base pairs. It has been used primarily in research settings for chromosome labeling and karyotyping due to its fluorescence properties. Mechanistically, it can inhibit trypanothione reductase in Trypanosoma cruzi and functions as an alkylating agent capable of cross-linking DNA strands, thereby interfering with DNA replication and transcription[1][5]. Quinacrine mustards were investigated as potential anticancer agents but have not advanced beyond early clinical trials[7].
- Other names
- quinacrine mustardmepacrine mustardacridine, 9-((4-(bis(2-chloroethyl)amino)-1-methylbutyl)amino)-6-chloro-2-methoxy-quinacrine mustard dihydrochloride
02
Targets
Trypanothione reductase
Beyond the preview
Go deeper on quinacrine mustard.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quinacrine mustard.